razormd

Indevus Pharmaceuticals: Nebido Has Lost Its Libido

While I agree that the FDA's decision was ludicrous I don't agree that it merits being called a "potential company-destroying two-year approval delay"...the company is generating substantial and increasing revenues from other products and has others well along in phase II and III...I really didn't think that nebido was all that worthy of development to begin with...with competing testosterone depot products I wondered what the profit and revenue potential would be...I also think they should finally dump that absurdity "pagoclone" -- the world doesn't need another benzodiazepene...compa... the company to the recently bought out TRCA I think IDEV should be north of $7 even without nebido.